From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: SMDS

Search articles by EPIC code
EPIC SMDS
views

DS Smith – a pleasing trading update

A new week and finally some good news from the United States for GSK plc (GSK) as the “FDA approves Boostrix for immunisation during pregnancy for the prevention of whooping cough in newborn infants”. It is not enough alone to start pushing the multinational pharmaceutical and biotechnology FTSE 100 name up, but it is a bit of good news for the company’s struggling CEO. As I have noted before, Dame Emma has a lot still to prove. Meanwhile, elsewhere in the FTSE 100, I am excited to see the over 8% rise in the shares today of DS Smith (SMDS).

EPIC SMDS
views

DS Smith remains much more glass half full than glass half empty for my pension fund

The thing about being an investor is that not everything goes your way. However, like any challenge or issue in life, what really matters is how you react. I have been a fan of DS Smith (SMDS), a leading multinational packaging business, I last talked about at length a few months ago. It has not been the greatest year for many stocks and DS Smith is among them. However I am not surprised that following today’s update in respect of the period since 1 May 2022, the shares are up this morning. Even more importantly, I think it is still a key FTSE 100 position for me.

Page 1 of 6 (53 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments